Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16760369rdf:typepubmed:Citationlld:pubmed
pubmed-article:16760369lifeskim:mentionsumls-concept:C0220908lld:lifeskim
pubmed-article:16760369lifeskim:mentionsumls-concept:C1539760lld:lifeskim
pubmed-article:16760369lifeskim:mentionsumls-concept:C0680240lld:lifeskim
pubmed-article:16760369lifeskim:mentionsumls-concept:C1510438lld:lifeskim
pubmed-article:16760369pubmed:issue6lld:pubmed
pubmed-article:16760369pubmed:dateCreated2006-9-14lld:pubmed
pubmed-article:16760369pubmed:abstractTextHigh-throughput screening (HTS) of large chemical libraries has become the main source of new lead compounds for drug development. Several specialized detection technologies have been developed to facilitate the cost- and time-efficient screening of millions of compounds. However, concerns have been raised, claiming that different HTS technologies may produce different hits, thus limiting trust in the reliability of HTS data. This study was aimed to investigate the reliability of the authors most frequently used assay techniques: scintillation proximity assay (SPA) and homogeneous time-resolved fluorescence resonance energy transfer (TR-FRET). To investigate the data concordance between these 2 detection technologies, the authors screened a large subset of the Schering compound library consisting of 300,000 compounds for inhibitors of a nonreceptor tyrosine kinase. They chose to set up this study in realistic HTS scale to ensure statistical significance of the results. The findings clearly demonstrate that the choice of detection technology has no significant impact on hit finding, provided that assays are biochemically equivalent. Data concordance is up to 90%. The little differences in hit findings are caused by threshold setting but not by systematic differences between the technologies. The most significant difference between the compared techniques is that in the SPA format, more false-positive primary hits were obtained.lld:pubmed
pubmed-article:16760369pubmed:languageenglld:pubmed
pubmed-article:16760369pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16760369pubmed:citationSubsetIMlld:pubmed
pubmed-article:16760369pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16760369pubmed:statusMEDLINElld:pubmed
pubmed-article:16760369pubmed:monthSeplld:pubmed
pubmed-article:16760369pubmed:issn1087-0571lld:pubmed
pubmed-article:16760369pubmed:authorpubmed-author:SchmidtAnneAlld:pubmed
pubmed-article:16760369pubmed:authorpubmed-author:ParczykKarste...lld:pubmed
pubmed-article:16760369pubmed:authorpubmed-author:von...lld:pubmed
pubmed-article:16760369pubmed:authorpubmed-author:KlotzMonikaMlld:pubmed
pubmed-article:16760369pubmed:issnTypePrintlld:pubmed
pubmed-article:16760369pubmed:volume11lld:pubmed
pubmed-article:16760369pubmed:ownerNLMlld:pubmed
pubmed-article:16760369pubmed:authorsCompleteYlld:pubmed
pubmed-article:16760369pubmed:pagination606-16lld:pubmed
pubmed-article:16760369pubmed:dateRevised2011-5-23lld:pubmed
pubmed-article:16760369pubmed:meshHeadingpubmed-meshheading:16760369...lld:pubmed
pubmed-article:16760369pubmed:meshHeadingpubmed-meshheading:16760369...lld:pubmed
pubmed-article:16760369pubmed:meshHeadingpubmed-meshheading:16760369...lld:pubmed
pubmed-article:16760369pubmed:meshHeadingpubmed-meshheading:16760369...lld:pubmed
pubmed-article:16760369pubmed:year2006lld:pubmed
pubmed-article:16760369pubmed:articleTitleAssay concordance between SPA and TR-FRET in high-throughput screening.lld:pubmed
pubmed-article:16760369pubmed:affiliationSchering AG, Enabling Technologies, Department of Assay Development & High Throughput Screening, Berlin, Germany. oliver.von_ahsen@schering.delld:pubmed
pubmed-article:16760369pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16760369lld:pubmed